Sameera Kumar

Dr. Sameera Kumar


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
SKSameera Kumar
Sameera Kumar
SCSteven Chmura
Steven Chmura
CRClifford Robinson
Clifford Robinson
SLSteven H. Lin
Steven H. Lin
SGShirish M. Gadgeel
Shirish M. Gadgeel
DMDrew Moghanaki
Drew Moghanaki

15 September 2020 in Current Oncology Reports
Verified
Journal Article
Closed access
PDF file
MLMaryanne J. Lubas
Maryanne J. Lubas
SKSameera Kumar
Sameera Kumar

30 November 2021 in Antioxidants
Verified
Journal Article
Open access
PDF file
SKSameera Kumar
Sameera Kumar
DSDaret St.Clair
Daret St.Clair
Prostate cancer occurs frequently in men and can often lead to death. Many cancers, including prostate cancer, can be initiated by oxidative insult caused by free radicals and reactive oxygen species. The superoxide dismutase family removes the oxygen-derived reactive oxygen species, and increased superoxide dismutase activity can often be protective against prostate cancer. Prostate cancer can be treated in a variety of ways, including surgery, androgen deprivation therapy, radiation therapy, and chemotherapy. The clinical trajectory of prostate cancer varies from patient to patient, but more aggressive tumors often tend to be radioresistant. This is often due to the free-radical and reactive-oxygen-species-neutralizing effects of the superoxide dismutase family. Superoxide dismutase 2, which is especially important in this regard, can be induced by the NF-κB pathway, which is an important mechanism in radioresistance. This information has enabled the development of interventions that manipulate the NF-κB mechanism to treat prostate cancer.

1 September 2019 in Translational Lung Cancer Research
Verified
Journal Article
Closed access
PDF file
SKSameera Kumar
Sameera Kumar
RMRonald C. McGarry
Ronald C. McGarry
Stereotactic body radiation therapy (SBRT) is a very effective way to treat early stage non-small cell lung cancer (NSCLC) and small oligometastatic lung lesions with consistently high rates of local control, but both local and regional/distant recurrences still occur. The management of recurrences remains unsettled and may entail repeat SBRT, conventionally fractionated external beam RT (EF-EBRT), chemotherapy or surgery. Most patients with local recurrences [within the initial planning target volume (PTV)] can be salvaged successfully with good cancer specific survival. Nonetheless, proximity of the initial SBRT delivery to organs at risk (ribs, blood vessels, airways) may make retreatment more difficult. With attention to detail and careful patient selection, both surgery and reirradiation can be performed safely and effectively. Strategies for management of regional (nodal) recurrences may require conventional therapies tailored to the patterns of failure. The role of immunotherapy in salvage has not been elucidated as yet. We review here data on the available literature concerning salvage of SBRT lung patients.

1 December 2021 in AME Surgical Journal
Verified
Journal Article
Open access
PDF file
GSGillian Saldanha
Gillian Saldanha
SKSameera Kumar
Sameera Kumar
Role of radiation treatment in multimodality treatment of malignant pleural mesothelioma: a narrative review Gillian Saldanha, Sameera Kumar

15 April 2020 in Preprints.org
Verified
Preprint
Open access
PDF file
SKSameera Kumar
Sameera Kumar
SCSteven Chmura
Steven Chmura
CRClifford Robinson
Clifford Robinson
SLSteven Lin
Steven Lin
SGShirish M. Gadgeel
Shirish M. Gadgeel
DMDrew Moghanaki
Drew Moghanaki
Importance: The COVID-19 pandemic is currently accelerating. Patients with locally advanced non-small cell lung cancer (LA-NSCLC) may require treatment in locations where resources are limited and the prevalence of infection is high. Patients with LA-NSCLC frequently present with comorbidities that increase the risk for severe morbidity and mortality from COVID-19. These risks may be further increased by treatments for LA-NSCLC. Observation: We present expert thoracic oncology multidisciplinary (radiation oncology, medical oncology, surgical oncology) consensus of alternative strategies for the treatment of LA-NSCLC during a pandemic. The overarching goals of these approaches are to reduce the number of visits to a healthcare facility, reduce the risk of SARS-CoV-2 exposure, and attenuate the immunocompromising effects of lung cancer therapies. Patients with resectable disease can be treated with definitive non-operative management if surgical resources are limited or the risks of perioperative care are high. Non-operative options include chemotherapy, chemoimmunotherapy, and radiation therapy with sequential schedules. The order of treatments may be based on patient factors and clinical resources. Whenever radiation therapy is delivered without concurrent chemotherapy, hypofractionated schedules are appropriate. For patients who are confirmed to have COVID-19, usually cancer therapies may be withheld until symptoms have resolved with negative viral test results. Conclusions and Relevance: The risk of severe treatment-related morbidity and mortality is significantly elevated for patients undergoing treatment for LA-NSCLC during the COVID-19 pandemic. Adapting alternative treatment strategies as quickly as possible may save lives and should be implemented through communication with the multidisciplinary cancer team.